RSS

Ario Pharma

New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates. more

XEN-D0501, a potent and selective small molecule inhibitor of TRPV1, has successfully completed multiple Phase I studies and been shown to be safe and well tolerated. more